肿瘤过继性细胞免疫治疗中CAR-T及TCR-T疗法研究进展
张青青?许莲蓉【摘要】近年来,新的生物技术不断被应用于临床,其中的肿瘤免疫治疗就是一种新型的抗肿瘤疗法。免疫治疗指在肿瘤微环境中,通过刺激免疫功能,增强抗肿瘤免疫,进而直接识别和杀伤肿瘤细胞。目前被应用于临床的肿瘤免疫治疗方法有免疫检查点治疗、细胞因子、肿瘤疫苗、过继性细胞免疫治疗(ACI)等。ACI是重要的肿瘤免疫治疗方法,由于ACI可以在不损害免疫系统及其功能的情况下杀死肿瘤细胞,而且能够避免肿瘤免疫逃逸,所以成为国内外研究的热点。经基因修饰改造T 淋巴细胞是ACI临床应用研究最深入的领域。经基因修饰改造的T淋巴细胞可分为嵌合抗原受体T细胞(CAR-T)及T细胞受体改造的T细胞(TCR-T),该文就CAR-T及TCR-T疗法的研究进展进行综述。
【关键词】肿瘤;过继性细胞;免疫治疗;嵌合抗原受体T细胞;T细胞受体改造的T细胞;
临床应用
Research progress on CAR-T and TCR-T in adoptive cellular immunotherapy for tumors Zhang Qingqing, Xu Lianrong. Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, China
Corresponding author, Xu Lianrong, E-mail: qing19834518006@ 163. com
【Abstract】In recent years, novel biological technologies have been constantly applied in clinical practice. Immunotherapy is considered as a new type of anti-tumor therapy. Immunotherapy in the tumor microenvironment stimulates immune function, enhances anti-tumor immunity, and then directly recognizes and kills tumor cells. At present, multiple immunotherapies have been utilized to treat tumors, such as immune checkpoint therapy ......
您现在查看是摘要页,全文长 17360 字符。